Solid performance across strategic brands with 19% growth in the first nine months of 2020; financial guidance range for 2020 narrowed
HIGHLIGHTS Revenue reached DKK 13,397 million in the first nine months of 2020, a growth of 6% (6% in local currencies) compared to 2019 with growth from all regions. The newest product in the portfolio, Vyepti[®], continues to pick up momentum doubling revenue compared to the second quarter of the year, despite the pandemic’s negative impact on HCP administered drugs. Cash flow saw a substantial improvement from same period last year driven by the strong operational performance. Growth continues to be driven by patient uptake due to the efficacy and reliability of the products in the